Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2560263 | 0.74 | — | — | |
| SCHEMBL17365147 | 0.72 | TACR1 (0.34) | LMNACYP2C9 | |
| SCHEMBL21101221 | 0.72 | — | — | |
| SCHEMBL14827659 | 0.68 | CRBN (0.32) | — | |
| SCHEMBL21101213 | 0.68 | LMNA (0.31) | LMNACYP2C9 | |
| SCHEMBL12681055 | 0.68 | LMNA (0.34) | LMNACYP2C9 | |
| SCHEMBL29348832 | 0.67 | — | — | |
| SCHEMBL21136845 | 0.67 | LMNA (0.31) | LMNACYP2C9 | |
| SCHEMBL22256986 | 0.66 | GRIN2D (0.34) | — | |
| SCHEMBL10738725 | 0.66 | LMNA (0.34) | LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428070-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190177320-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177320-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | LMNA 2852/4885CYP2C9 685/4885 |
| US-10428070-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | LMNA 2852/4885CYP2C9 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.